In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main
  • Posted: 01/07/2004

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Gefitinib for Non-Small Cell Lung Cancer Trial

Name of the Trial

Phase III Randomized Study of Adjuvant Gefitinib in Patients with Completely Resected Primary Stage IB, II, or IIIA Non-Small Cell Lung Cancer (CAN-NCIC-BR19). See the protocol summary.

Principal Investigators

Dr. Glenwood Goss of the National Cancer Institute of Canada; Dr. Gregory A. Masters of the Eastern Cooperative Oncology Group; and Dr. Peter Roberts of the Southwest Oncology Group.

Why This Trial Is Important

Lung cancer is the second most common cancer and is the leading cause of cancer death in the United States. The more common type is non-small cell lung cancer, which grows slower than the more aggressive small cell lung cancer.

Biological therapies such as gefitinib (Iressa™) may interfere with and slow the growth of tumor cells. Furthermore, gefitinib, a targeted therapy, belongs to a new class of agents that generally have less severe side effects than those associated with traditional chemotherapy.

This study seeks to assess the effectiveness of gefitinib in prolonging the survival of patients who have undergone surgery for stage IB, II, or IIIA non-small cell lung cancer.

"We know from previous studies that chemotherapy can improve survival in patients with early-stage non-small cell lung cancer," said Dr. Goss. "What we seek to establish now is whether or not gefitinib can further improve the survival benefit, and do so with more tolerable side effects than one would experience with classic chemotherapy agents."

Contact Information

This trial is no longer recruiting new patients. To locate other lung cancer clinical trials, search the NCI's database of clinical trials or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.